Director/PDMR Shareholding
28 December 2017 14:00 GMT TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES - AMENDMENT Disclosure under Article 19 of the EU Market Abuse Regulation AstraZeneca PLC (the Company) announces that the notification made in accordance with the requirements of the EU Market Abuse Regulation on 15 December 2017 relating to a change in the beneficial interest in the Company's Ordinary Shares of US$0.25 each of Mr Soriot has been amended, as set out in the revised notification below. 1 Details of the person discharging managerial responsibilities / person